During the Stifel 2026 Targeted Oncology Virtual Forum, Andrew Peters, the Senior Vice President of Strategy at Exelixis, provided insights into the company's development efforts for Zanza, a treatment for various tumor types. He noted that the upcoming December PDUFA date for Zanza in third-line colorectal cancer, based on data from the STELLAR-303 trial, is a significant milestone for the company. Peters emphasized the importance of the regimen's value proposition in this setting and discussed the potential for identifying specific subsets of patients who may benefit the most from Zanza. He reiterated Exelixis' strategy of building a franchise around Zanza, which aligns with the company's broader goals in oncology. The conversation included forward-looking statements, highlighting the risks associated with their business and the regulatory landscape. Overall, the forum underscored Exelixis' commitment to advancing its oncology pipeline and addressing the needs of patients with challenging cancers.